Kathryn Smalley

MESM Global are proud to announce the launch of QRTD (Quantitative Real Time Diagnostics). MESM have officially partnered with Abbott POC and Abaxis for use of their diagnostic devices/services for the global clinical trials market. On site test results across a multitude of testing parameters gives you the ability to reduce the number of patient visits to site, enabling an improved patient experience and reduced study costs. The partnership covers so much more than just the provision of these devices, through this comprehensive partnership, MESM can offer: • Customized training & support • Technical support • Regulatory consultancy • Global logistics • Equipment management for life MESM will be exhibiting at the upcoming PCT event Barcelona 5th – 6th November. Come and visit us at booth number 225. We look forward to seeing you QRTD is already in use, a global phase III study involving 29 countries, offering standardized results, has proven QRTD’s place in the global clinical trials market. MESM have become the partner of choice for many sponsors and CRO’s alike, offering total equipment solutions to global and local clinical trials, it is because of this that both Abbott and Abaxis join us in bringing this service to the clinical trials market, a service that is tailored to your needs, your protocol. QRTD: Results, When you need them. For more information on this partnership, or to find out more about the testing parameters available, please contact [email protected]